GenSight will participate to the 21st annual meeting ASGCT in Chicago (IL) and will present 3 posters related to both clinical-stage product candidates GS010 to treat LHON and GS030, an optogenetics approach for Retinitis Pigmentosa (RP).
GS010 – Leber’s Hereditary Optic Neuropathy (LHON)
Poster Title: Sequential Bilateral Intravitreal Injection of GS010 (rAAV2/2-ND4) Separated by a 15-Day or a 3-Month Interval in Non-Human Primates: Good Safety and Immunogenicity Profile
- Session Date/Time: Wednesday May 16, 2018 5:30 PM – 7:30 PM
- Session title: AAV Vectors I
- Room: Stevens Salon C, D
- Final abstract number: 93
GS030 – Optogenetics in Retinitis Pigmentosa (RP)
Poster Title: GS030-DP, an AAV2.7m8-ChrimsonR-tdTomato Gene Therapy Product for Retinitis Pigmentosa Treatment, is Well Tolerated in Monkeys and rd1 Mice after Bilateral Intravitreal Administration
- Session Date/Time: Friday May 18, 2018 5:45 PM – 7:45 PM
- Session title: Neurologic Diseases (Including Ophthalmic and Auditory Diseases) III
- Room: Stevens Salon C, D
- Final abstract number: 881
Poster Title: A Robust, Highly Sensitive Cell-Based Assay for Potency Measurement of the AAV-Vectorized Optogenetic Therapy, GS030-DP, Developed to Treat Retinitis Pigmentosa
- Session Date/Time: Thursday May 17, 2018 5:15 PM – 7:15 PM
- Session title: AAV Vectors II
- Room: Stevens Salon C, D
- Final abstract number: 403